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Abstract
Background: Testes-specific protease 50 (TSP50), a newly discovered threonine enzyme, has similar amino acid sequences
and enzymatic structures to those of many serine proteases. It may be an oncogene. TSP50 is up-regulated in breast cancer
epithelial cells, and ectopic expression of TSP50 in TSP50-deficient Chinese hamster ovary (CHO) cells has been found to
promote cell proliferation. However, the mechanisms by which TSP50 exerts its growth-promoting effects are not yet fully
understood.
Methodology/Principal Findings: To delineate whether the threonine protease activity of TSP50 is essential to its function
in cell proliferation, we constructed and characterized a mutant TSP50, called TSP50 T310A, which was identified as
a protease-dead mutant of TSP50. By a series of proliferation analyses, colony formation assays and apoptosis analyses, we
showed that T310A mutation significantly depresses TSP50-induced cell proliferation in vitro. Next, the CHO stable cell line
expressing either wild-type or T310A mutant TSP50 was injected subcutaneously into nude mice. We found that the T310A
mutation could abolish the tumorigenicity of TSP50 in vivo. A mechanism investigation revealed that the T310A mutation
prevented interaction between TSP50 and the NF-kBIkBa complex, which is necessary for TSP50 to perform its function in
cell proliferation.
Conclusion: Our data highlight the importance of threonine 310, the most critical protease catalytic site in TSP50, to TSP50-
induced cell proliferation and tumor formation.
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Introduction
Testes-specific protease 50 (TSP50) was discovered on a hypo-
methylated DNA fragment isolated from human breast cancer
cells using the methylation-sensitive representational difference
analysis technique [1]. TSP50 transcripts have been detected
predominantly in human testes and are not visible in other normal
tissues. However, most patients with breast cancer or colorectal
carcinoma show abnormal TSP50 activation and expression
[2,3,4]. Downregulation of TSP50 expression has been found to
reduce cell proliferation and colony formation [5]. Our previous
studies have revealed that the overexpression of TSP50 in CHO
cells can markedly promote cell proliferation and colony formation
in vitro and stimulate tumor formation in nude mice [6]. These
results indicate that TSP50 could be an oncogene.
TSP50 is a member of the peptidase S1 family of serine
proteases. Serine proteases carry out a diverse array of
physiological and cellular functions, ranging from digestive and
degradative processes to blood clotting, cellular and humoral
immunity, embryonic development, fibrinolysis, fertilization, pro-
tein processing, and tissue remodeling [7]. Serine proteases have
been classified into evolutionarily unrelated clans, which have
been subdivided into families of proteases whose homology can be
established statistically [8,9]. Serine proteases are characterized by
an active serine in their catalytic site. Two other residues,
a histidine and an aspartate, are associated with the active serine,
constituting what is referred to as the ‘‘catalytic triad’’ in many
families of serine proteases, including the trypsin (S1), subtilism
(S8), prolyl oligopeptidase (S9), and serine carboxypeptidase (S10)
families [9,10]. The positions of these residues are more or less
conserved, with the codons for the catalytically essential histidine
and serine being almost immediately adjacent to their exon
boundaries [8,9].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e35030TSP50 is homologous to many serine proteases and contains
a peptidase S1 domain (93–358). The amino acid sequence
alignment of TSP50 with seven serine proteases showed that it
shares 26–36% identity with those proteases. Enzymatic structures
are also very similar [2,11]. However, the catalytic triad of TSP50
is different from that of traditional serine proteases. TSP50
contains the first two sites of the catalytic triad, His and Asp, at
positions 153 and 206, respectively. However, the third site, Ser, at
position 310, is replaced by threonine. In this way, TSP50
represents a novel classification because of its Thr310 residue
substitution, which may play an important catalytic role [11].
The threonine catalytic site of TSP50 is crucial to its protease
activity [11]. However, whether this threonine catalytic site is
necessary to the ability of TSP50 to promote cell proliferation
remains to be determined. In this study, we used site-directed
mutagenesis and a series of the cell proliferation and tumorige-
nicity assays to show that the TSP50 T310A mutation could
abolish the cell-proliferation-promoting function of TSP50.
Further studies demonstrated that the TSP50 T310A mutation
could destroy the interaction between TSP50 and the NF-kB:IkBa
complex, which is necessary for TSP50 to perform its function in
cell proliferation. These results indicate that threonine 310, the
most critical protease catalytic site of TSP50, is essential to the
interaction between TSP50 and the NF-kB:IkBa complex and
therefore TSP50’s role in cell proliferation. The dominant
negative mutant allele constructed in this study may further
understanding of the TSP50 and may be useful in cancer therapy.
Results
Structure of TSP50
The structure of human TSP50 was predicted and visualized in
PyMOL. As shown in Figure 1, TSP50 consists of a peptidase
chymotrypsin (S1) domain (93–358), which contains the catalytic
triad. The catalytic triad consists of a histidine at position 153, an
aspartic acid at position 206, and a threonine, the most critical
protease catalytic site of TSP50, at position 310. In the peptidase
S1 family, there is usually a serine. In this way, TSP50 could
represent a new kind of serine protease. The catalytic triads of
TSP50 were found to be located near the opening of the pocket,
which is formed by two groups of b sheet structures. This structure
may provide the proteins with selective access to the threonine
catalytic site of TSP50.
Acquisition of Cell Strains Stably Expressing TSP50 and
TSP50 T310A Mutation
TSP50 contains a distinctive catalytic triad and the threonine
catalytic site within this catalytic triad is crucial for its protease
activity [2,11]. Besides protease activity, TSP50 has also been
shown to facilitate cell proliferation [5,6]. To determine whether
protease activity is essential to TSP50-mediated promotion of cell
growth, we established a point mutant construct of TSP50, TSP50
T310A, a protease-dead mutant [11].
Our previous study has shown that overexpression of TSP50 in
CHO cells markedly promoted cell proliferation and colony
formation in vitro. To determine the effects of point mutation on
TSP50-mediated promotion of cell growth, plasmids carrying
either a wild-type TSP50 gene or the mutant were transfected into
CHO cells. Stably transfected cell lines were obtained by G418
selection. The same cell line stably transfected with empty plasmid
was used as a negative control, here called pcDNA3 cells. The cell
line stably transfected with wild-type TSP50 is here called
pcDNA3-TSP50 cells. Stable cell line carrying the TSP50 mutant
was named after its mutated form, pcDNA3-TSP50 T310A cells.
RT-PCR (Figure 2A) and Western blot analysis (Figure 2B)
confirmed the mRNA and protein expression of various TSP50s in
the stably transfected cells. The results showed that the levels of all
TSP50 proteins were similar. In this way, these cell strains showing
stable expression of TSP50 and its point mutant were available for
further functional analysis. Prior study has shown that TSP50 was
located in the ER and cytoplasmic membrane [11]. To determine
whether there had been any change in cellular localization of the
mutant TSP50, pEGFP-N1, pEGFP-TSP50, and pEGFP-TSP50
T310A were transfected into 293T cells. They were monitored by
confocal microscopy. As shown in Figure 2C, pEGFP-TSP50 and
pEGFP-TSP50 T310A showed similar cellular localization and
the mutation was not found to change the cellular localization of
TSP50.
Effects of Point Mutation TSP50 T310A on TSP50-
mediated Promotion of Cell Growth
To compare the effects of wild-type TSP50 to those of its
mutant on cell proliferation, we evaluated the cell proliferation
capacity of stable cell lines expressing different TSP50s. MTT cell
proliferation assay showed that, compared to negative pcDNA3
cells, pcDNA3-TSP50 cells grew very quickly. This was consistent
with previous reports. However, the growth rate of pcDNA3-
Figure 1. Predicted structure of human TSP50. a-helices (pink), b-
sheets (orange), and loops (green) are labeled in this predicted
structure of homo-sapiens TSP50 (113–369). The positions of amino
acids within the catalytic triad are shown. The catalytic triad consists of
a histidine at position 153, an aspartic acid at position 206, and
a threonine, the most critical protease catalytic site of TSP50, at position
310. This diagram was prepared using PyMOL.
doi:10.1371/journal.pone.0035030.g001
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(Figure 3A). BrdU incorporation assay also showed that the
increased uptake of BrdU by overexpression of TSP50 was
eliminated by the point mutant TSP50 T310A (Figure 3B). We
observed similar results in other cell lines. Plasmids carrying either
a wild-type TSP50 gene or the mutant were also transfected into
human hepatic L02 cells and a BrdU incorporation assay was
performed. Human hepatic L02 cells express TSP50 endogenously
(Figure 3C) and pcDNA3-TSP50 L02 cells grew slightly faster
than pcDNA3 L02 cells (Figure 3D). However, TSP50 T310A
severely restrained the growth of human hepatic L02 cells
(Figure 3D).
Colony formation assays allow simple and direct assessment of
the anchorage-independent growth capacity of colony-forming
cells [12,13,14]. As indicated in Figures 3E, 3F, and 3G, pcDNA3-
TSP50 cells formed much larger colonies than those formed by
pcDNA3 cells, whereas the colonies formed by pcDNA3-TSP50
T310A cells were similar to those formed by pcDNA3 cells. Taken
together, these data indicate that the point mutation TSP50 T310
can abolish the cell-growth-promoting activity of TSP50, suggest-
ing that protease activity is required for TSP50 to promote cell
proliferation.
It had been shown that the growth rate of transplanted CHO
cells depends on the level of fibronectin receptor expressing on the
cell surface [15]. Considering that TSP50 is associated with
cellular membranes, this suggests that alsoTSP50 exerts its
enzymatic activity on the cell membrane, where it can cleave
ECM-receptors and other targets [11]. To address the functional
connection between expression of the fibronectin receptor and
activity of TSP50, we performed scratch-wound assay on
fibronectin-coated plates. As shown in Figure 3H, migration of
pcDNA3-TSP50 cells into the gap was much quicker than that of
pcDNA3 cells. However, wound closure was greatly inhibited in
the pcDNA3-TSP50 T310A cells (Figure 3H). Considering that
the mutation did not change the cellular localization of TSP50
(Figure 2C), these data indicate that TSP50, as a threonine
protease, may also exert its cell-growth-promoting function
partially through cleavage of ECM receptors.
Analysis of the Pro-proliferative and Anti-apoptotic
Function of TSP50 Based on the Flow Cytometry Analysis
Upon reaching confluency, CHO cells showed no contact-
induced growth arrest, but they did undergo high-density
dependent apoptosis [16]. Figure 3A shows that, until day 4 there
was no significant difference in the growth kinetics of stable
transfected CHO cells. However, the difference became obvious
after day 4, indicating that TSP50 might protect cells from high-
density induced apoptosis. To strengthen the proposed pro-
proliferative function of TSP50 and to confirm (or exclude) its
anti-apoptotic effects, we undertook a careful analysis of cell cycle
progression and apoptosis in the cells grown for 96 h in complete
medium. Flow cytometry analysis showed that wild-type TSP50
could accelerate the G1-S transition and protect CHO cells from
cell-density-dependent apoptosis (Figure 4A and 4B). However,
TSP50 T310A was found to abolish the pro-proliferative function
of TSP50, as indicated by the lack of acceleration of the G1-S
transition in CHO cells transfected with TSP50 T310A, but it can
still protect CHO cells from cell-density-dependent apoptosis
(Figure 4A and 4B). This implies that protease activity of TSP50 is
essential for its pro-proliferative function but not for enhancing its
resistance to density-induced apoptosis.
We also detected levels of some cell cycle regulatory factors in
cells expressing TSP50 and cells expressing TSP50 T301A.
Figure 2. Analysis of TSP50 and TSP50 T310A expression and cellular localization. (A) TSP50 mRNA levels in pcDNA3 cells, pcDNA3-TSP50
cells and pcDNA3-TSP50 T310A cells were analyzed using RT-PCR. b-actin was used as an internal control to check the efficiency of cDNA synthesis
and PCR amplification. (B) TSP50 protein levels in pcDNA3 cells, pcDNA3-TSP50 cells and pcDNA3-TSP50 T310A cells were analyzed by Western
blotting. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. (C) Cellular localization of TSP50 and TSP50 T310A
were determined in 293T cells transiently transfected with either pEGFP-TSP50 or pEGFP-TSP50 T310A by confocal microscopy. The right and left
panels show the fluorescent and bright fields respectively. pEGFP-N1 empty vector was used as control.
doi:10.1371/journal.pone.0035030.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e35030Consistent with the flow cytometry analysis of the cell cycle shown
in Figure 4A, overexpression of TSP50 was found to elevate the
expression of cyclin D1 and cyclin E, which can accelerate the G1-
S transition. In addition, the expression of p27 and p21, which can
inhibit the activity of all G1 cyclin/cdk complexes, was suppressed
in pcDNA3-TSP50 cells. However, the TSP50 T310A mutation
abolished all of these effects (Figure 4C).
Effects of Point Mutation TSP50 T310A on TSP50-
mediated Resistance to DOX-induced Apoptosis
Doxorubicin (DOX), a widely used chemotherapeutic agent,
can induce apoptosis in various types of cancer cells [17,18].
Previous studies have shown that knockdown of TSP50 by RNA
interference can result in increased sensitivity to DOX-induced
apoptosis in P19 cells [5]. We then investigated whether
overexpression of TSP50 could enhance the resistance to DOX-
induced apoptosis in CHO cells and whether this activity could be
abolished by point mutation TSP50 T310A. As shown in
Figure 5A, overexpression of TSP50 inhibited DOX induced
activation of caspase-3, while knockdown of TSP50 could reverse
the sensitivity of CHO cells to DOX-induced apoptosis (Figures 5B
and 5C). TUNEL assay also confirmed that pcDNA3-TSP50 cells
could enhance the resistance of CHO cells to DOX-induced
apoptosis and that this effect could be abolished by the point
mutation T310A (Figure 5D).
Abolishment of TSP50-mediated Tumorigenicity by Point
Mutation TSP50 T310A
Because TSP50 T310A mutation can abolish the activity of
TSP50 to promote cell growth, we then determined whether they
also affect the tumorigenicity of TSP50. We injected 5610
6 cells
from each stable CHO cell line expressing either wild-type or
point mutant TSP50 into the subcutaneous tissue of each athymic
(nude) mouse. As in previous studies, the growth rate of tumors
derived from pcDNA3-TSP50 cells were faster than that of tumors
originating from pcDNA3 cells (Figures 6A and B) and the tumors
in pcDNA3-TSP50 cells were heavier as well (Figures 6C and D).
However, the growth rates and the weights of tumors derived from
pcDNA3-TSP50-T310A-expressing cells were similar to those in
pcDNA3 cells (P.0.05). Next, tumors from each group were
subjected to immunohistochemical analysis with antibodies against
Ki67. The results showed that TSP50-dependent hyperprolifera-
tion is impaired in tumors derived from CHO cells expressing
TSP50 T310A (Figure 6E). These observations provide strong
evidence that the ability of TSP50 to promote cell proliferation is
abolished by the TSP50 T310A point mutation.
Abolishment of the Interaction of TSP50 with NF-kB:IkBa
Complex and Effects on NF-kB Signaling
Increasing evidence suggests that the NF-kB signaling path-
ways play important roles in inflammation and tumor de-
velopment [19,20,21,22]. It has been shown that inflammation
and tumorigenesis are closely linked processes [23,24,25]. In
mammals, the NF-kB family is composed of five related
transcription factors, p50, p65 (also RelA), p52, c-Rel, and
RelB. These transcription factors share an N-terminal DNA-
binding/dimerization domain, called the Rel homology domain,
through which they can form homo- and heterodimers. In most
cells, NF-kB dimers are inactive, residing predominantly in the
cytoplasm in a complex with inhibitory IkB proteins (IkBa,
IkBb,I kBe,I kBf, p100, p105, Bcl3, and IkBns). When
signaling pathways are activated, the IkBs protein is degraded
and NF-kB dimers enter the nucleus to modulate target gene
expression [26,27].
Our prior studies have shown that TSP50 can interact with
the NF-kB:IkBa complex and activate the NF-kB signaling
pathway. This could be one of the mechanisms underlying
TSP50-mediated promotion of cell proliferation [6]. To de-
termine how the TSP50 T310A mutation abolishes the effects of
TSP50 on cell proliferation, the ability of the mutant TSP50s to
interact with NF-kB:IkBa complex and to promote NF-kB
signaling were examined. TSP50 T310A mutants were not found
to interact with the NF-kB:IkBa complex under the same
conditions as wild-type molecules (Figure 7A). This strongly
suggests that TSP50 needs to combine with the NF-kB:IkBa
complex to promote cell proliferation. Immunoblotting showed
that the degradation of IkBa in pcDNA3-TSP50 T310A cells
was delayed (Figure 7B), and the translocation of NF-kB p65 to
the nucleus was decelerated after PMA treatment compared with
pcDNA3-TSP50 cells (Figures 7C). PMA is an established NF-kB
activator [28]. Furthermore, NF-kB signaling activity reporter
assay also showed that the T310A mutation dramatically
abolished the enhancement of pNF-kB-luc luciferase activity by
TSP50 (Figure 7D). We also performed chromatin immunopre-
cipitation (ChIP) to analyze the recruitment of p65 to the cyclin
D1 promoter, which has NF-kB binding sites. Results showed
that the recruitment of p65 to the cyclin D1 promoter was more
pronounced in L02 cells transfected with pcDNA3-TSP50 than
in L02 cells transfected with pcDNA3 empty vector. However,
TSP50 T310A blocked the recruitment of p65 to the cyclin D1
promoter (Figure 7E). Next, we investigated the protein levels of
some NF-kB target genes in both TSP50- and TSP50 T301A-
expressing cells. As shown in Figures 7F, 7G, and 7H,
overexpression of TSP50 enhanced the expression of cyclin D1,
Cox-2, and C-myc after cells had been pretreated with PMA for
4 h. However, overexpression of TSP50 T310A failed to
enhance PMA-induced expression of these NF-kB target genes
(Figures 7F, 7G, and 7H). These observations provide strong
evidence that TSP50 needs to combine with NF-kB:IkBa
complex to promote cell proliferation and T310A mutation
impairs TSP50’s ability to facilitate cell proliferation at least
partly through destroying TSP50’s abilities to interact with NF-
kB:IkBa complex.
Figure 3. Promotion of cell proliferation by TSP50 is abolished by T310A point mutation. (A) The effects of TSP50 and TSP50 T310A on
cell proliferation of CHO cells were determined by MTT assay. The experiments were repeated three times with similar results. (B) Effects of TSP50 and
TSP50 T310A on cell proliferation of CHO cells were determined by BrdU incorporation assay. Results are representative of three independent
experiments. (C) TSP50 protein levels in pcDNA3 L02 cells, pcDNA3-TSP50 L02 cells, and pcDNA3-TSP50 T310A L02 cells were analyzed by Western
blotting. GAPDH was used as a loading control. (D) Effects of TSP50 and TSP50 T310A on cell proliferation of human hepatic L02 cells were
determined by BrdU incorporation assay. Results are representative of three independent experiments. (E) Effects of TSP50 and TSP50 T310A on
colony formation ability of CHO cells were determined by soft agar colony formation assays. Viable colonies were stained with 5 mg/ml of MTT
15 days after plating, and then the plates were photographed. (F) The number of colonies with diameters over 1 mm in each dish was determined.
**indicates P , 0.01 with respect to the value for pcDNA3 cells. (G) The representative colony size of each experimental group is shown. (H) Scratch-
wound assay on fibronectin-coated plates. Cells were seeded into fibronectin-coated (10 mg/ml) six-well plates in DMEM and cultured overnight.
Photographs were taken 24 h after the wound was made. The experiment was repeated three times and similar results were obtained each time.
doi:10.1371/journal.pone.0035030.g003
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TSP50’s Ability to Interact with NF-kB:IkBa Complex
The co-immunoprecipitation assay showed that mutated TSP50
T310A could not interact with the NF-kB:IkBa complex
(Figure 7A). To determine how mutation of threonine 310
structurally blocks TSP50-IkBa:NF-kB interactions, we performed
a molecular dynamics simulation focusing on the structural
modifications caused by the mutation. We noted that the mutated
model presented some changes in flexibility along the edge of the
active pocket, so we calculated the RMSF value of every aC atom
in both models. We found several sharp reductions in residue
flexibility in the mutated model, and these reductions were
enriched in residues No. 44–48, 74–86, 118–125, and 168–173
(Figure 8A). Advanced analysis indicated that notable parts of
these residues were located near the edge of the active pocket of
the TSP50 model (Figure 8B).
Discussion
Serine proteases have demonstrated roles in tumor growth
[29,30]. For example, there is a strong correlation between
urokinase plasminogen activator levels and greater metastatic
potential in breast cancer [31]. TSP50, a newly discovered
threonine protease, contains amino acid sequences and enzymatic
structures similar to those of many serine proteases. It has been
shown that overexpression of TSP50 can promote cell pro-
liferation and colony formation in vitro and stimulate tumor
formation in nude mice [6]. It has also been shown that
knockdown of TSP50 in mouse P19 cells can inhibit tumor cell
proliferation and induce apoptosis [5]. Further understanding of
TSP50 biology may provide additional mechanistic insights into
role of serine proteases in cell proliferation.
As a novel threonine protease, the catalytic triad of TSP50,
especially Thr310, is crucial for its protease activity [11]. In this
study, we show that the TSP50 T310A mutation can impair the
ability of TSP50 to promote cell proliferation, colony formation,
and tumorigenicity (Figures 3 and 6). This provides strong
evidence that the threonine protease activity of TSP50 is pivotal
to TSP50-dependent hyperproliferation, anchorage-independent
growth, and tumor formation.
Previous research has shown that knockdown of TSP50 by
RNA interference can strengthen DOX-induced apoptosis in P19
cells [5]. Here we showed that overexpression of TSP50 can
enhance resistance to DOX-induced apoptosis in CHO cells while
overexpression of TSP50 T310A cannot (Figures 5A and 5D).
This indicates that the threonine protease activity of TSP50 is also
important for the anti-apoptotic function of TSP50. In addition,
flow cytometry analysis (Figures 4A) showed that TSP50 over-
expression reduced high-density induced apoptosis from 26.51%
to 22.98%. This implied that overexpression of TSP50 could also
enhance resistance to high-density-induced apoptosis. However,
although overexpression of TSP50 T310A could not enhance the
resistance to DOX-induced apoptosis in CHO cells (Figures 5A
and 5D), overexpression of TSP50 T310A seem to protect CHO
cells from high-density induced apoptosis (13.81%) relative to
pcDNA3 cells (26.51%). This may be because pcDNA3-TSP50
T310A cells grew too slowly to induce high-density dependent
apoptosis. The S stage of pcDNA3 cells is 15.19%, but that of
pcDNA3-TSP50 T310A cells is only 8.25% (Figure 4A).
Our recent studies have shown that TSP50 can interact with
NF-kB:IkBa complex and promote NF-kB signaling pathway to
facilitate cell proliferation [6]. Here, we found that mutant TSP50
T310A lost its ability to interact with NF-kB:IkBa complex under
certain conditions. Furthermore, mutant TSP50 T310A affects
IkBa degradation and NF-kB p65 translocation into the nucleus
compared with TSP50 expressing cells (Figure 7). These results
indicate that IkBa could be a major target of TSP50 and that
TSP50 may increase IkBa degradation by direct interaction. In
addition, the TSP50 T310A mutation exerts a dominant-negative
effect, at least partially through destroying the ability of TSP50 to
interact with the NF-kB:IkBa complex and further affects the
enhancement of IkBa degradation and NF-kB p65 nuclear
translocation facilitated by TSP50.
We have also shown several sharp reductions in residue-
flexibility in the mutated model. Notable parts of these residues are
located near the edge of the active pocket of the TSP50 model
(Figure 8). Considering that these pocket-edge residues have large
side chains, we suspected that the reduction of the flexibility of the
pocket-edge might weaken the capability of the active pocket edge
to fit the substrates.
In conclusion, the results obtained here indicate that the
threonine protease activity of TSP50 is essential to its function in
hyperproliferation, anchorage-independent growth, tumor forma-
tion, and DOX-induced apoptosis. In addition, the T310A
mutation exerts its dominant-negative effect at least partially
through the destruction of TSP50’s ability to interact with NF-
kB:IkBa complex. This affects IkBa degradation and NF-kB p65
translocation into the nucleus compared with TSP50 expressing
cells. These findings lend insight into the mechanism by which
TSP50 enhances cell proliferation though its protease activity. The
dominant negative mutant allele constructed in this report may
further our understanding of the TSP50 gene.
Materials and Methods
Ethical Treatment of Animals
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approvedbytheCommitteeontheEthicsofAnimalExperimentsof
Northeast Normal University (Permit Number: SCXK 2009-0004).
All surgery was performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering.
Cell Lines and Cell Culture
Chinese hamster ovary (CHO) cells, human embryonic kidney
(HEK293T) cells and human hepatic L02 cells were obtained from
Cell Bank of the Chinese Academy of Sciences (Shanghai, China).
The cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco), supplemented with 10% fetal bovine serum
(FBS, TBD, China) and antibiotics (100 U/ml penicillin and
100 mg/ml streptomycin).
Figure 4. Analysis of the pro-proliferative and anti-apoptotic function of TSP50 based on the flow cytometry analysis. (A) Cell cycle
analysis. Flow cytometric detection of cell cycle by propidium iodide fluorescence were conducted in pcDNA3 cells, pcDNA3-TSP50 cells and pcDNA3-
TSP50 T310A cells harvested after 96 h of growth in complete medium. (B) Annexin V/PI staining assay. pcDNA3 cells, pcDNA3-TSP50 cells, and
pcDNA3-TSP50 T310A cells were grown for 96 h in complete medium, stained with Annexin V and propidium iodide, and analyzed by flow cytometry.
(C) Effects of TSP50 and TSP50 T310A on the levels of cell cycle regulatory proteins. The cyclin E, cyclin D1, p27, and p21 levels in pcDNA3 cells,
pcDNA3-TSP50 cells, and pcDNA3-TSP50 T310A cells were detected by Western blotting. GAPDH was used as a loading control.
doi:10.1371/journal.pone.0035030.g004
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The TSP50and itspointmutationconstruct wereclonedintothe
pcDNA3 basic vector and pEGFP-N1 vector. The point mutation
construct pcDNA3-TSP50 T310A, originating from the construct
pcDNA3-TSP50, was amplified by PCR. The point mutation
construct was created using a Site Directed Mutagenesis Kit
Figure 5. Effects of T310A point mutation on TSP50-mediated resistance to DOX-induced apoptosis. (A) pcDNA3 cells, pcDNA3-TSP50
cells, and pcDNA3-TSP50 T310A cells were treated with 5 mg/ml of DOX for 12 h, and cleaved-caspase 3 protein levels in these cells were detected by
Western blotting. GAPDH was used as a loading control. (B) S-shRNA, TSP50 shRNA#1, and TSP50 shRNA#4 were transfected into pcDNA3-TSP50
cells, and the TSP50 mRNA levels of these cells were analyzed by RT-PCR. b-actin was used as an internal control to check the efficiency of cDNA
synthesis and PCR amplification. (C) S-shRNA, TSP50 shRNA#1, and TSP50 shRNA#4 were transfected into pcDNA3-TSP50 cells, and cleaved-caspase
3 and TSP50 protein levels in these cells were detected by Western blotting after pretreatment with 5 mg/ml of DOX for 12 h. GAPDH was used as
a loading control. Quantification of WB for TSP50 levels using ImageJ software is shown on the left panel. (D) Cells were treated with 5 mg/ml of DOX
for 12 hours and stained using the TUNEL Assay Kit (Cat. no 12 156 792 910 Roche Applied Sciences, Mannheim, Germany).
doi:10.1371/journal.pone.0035030.g005
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andlowerrorrateofthemethodrendertheanalysisoflargenumbers
of subclones unnecessary [32]. The primer sequences used were as
follows: TSP50 T310A-For GTTCTGCTATGAGCTAGCTG-
GAGAGCCCTTGGTC, Rev GACCAAGGGCTCTCCAGC-
TAGCTCATAGCAGAAC. To create the TSP50 shRNA expres-
sion vector, the pRNAT-U6.1/Hygro vector (GenScript
Corporation, NJ, U.S.) was used for DNA vector-based shRNA
synthesis. pRNAT-U6.1/Hygro expresses hairpin sequences which
utilize the U6 RNA pol III promoter, and it also has a coral GFP
marker (cGFP) under CMV promoter control. For each target, the
senseandantisensestrandswereseparatedbyaloopthatcomprised
ninenucleotides(5’-TTCAAGAGA-3’)andapolythymidinetractto
terminate transcription. The shRNA sequences targeting TSP50
were TSP50 shRNA#1 AAGTTCTGCTATGAGCTAACT and
TSP50shRNA#4GAGTGTGACAATTTCTACC.Thesequence
of the scrambled shRNA negative control (GenScript Corporation,
NJ, U.S.) was GACGCTTACCGATTCAGAA. Thissequence has
no significant homology to any known mouse or human gene
sequence.
Antibodies
Rabbit polyclonal antibodies against IkBa, p27, cyclin E, COX-
2, Ki67 and mouse monoclonal antibodies against p65, p21, cyclin
Figure 6. Promotion of tumor growth in NOD/SCID mice by TSP50 is abolished by T310A mutation. 5610
6 cells of indicated cells were
suspended in physiological saline and injected subcutaneously into the back of the cohorts of 7 BALB/C-scid mice. After 16 days, mice were killed and
tumors were removed. (A) The photographs of all the NOD/SCID mice from each group at the end of the experiments. (B) Average tumor volume of
each group (n=7). * Student’s t-test analysis indicated that there was statistical significance in differences between pCDNA3-TSP50 group and
pCDNA3 group. (C) Photographs of all the dissected tumors from each group. (D) Average tumor weight of each group. Statistical analysis was
performed using the Student’s t test. (E) Immunohistochemical analysis of Ki67 expression in histological sections of tumors from each experimental
group. Scale bar: 20 mm.
doi:10.1371/journal.pone.0035030.g006
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(Santa Cruz, CA, U.S.). Rabbit polyclonal antibody against
cleaved caspase-3 was obtained from Cell Signaling Technology
Inc. (Beverly, MA, U.S.), and mouse monoclonal antibody against
GAPDH was purchased from Kangcheng Biotech (Shanghai,
China). Anti-TSP50 monoclonal antibody was prepared in our
laboratory [33].
Modeled Structure of TSP50
The one-letter amino acid sequence of TSP50 was obtained
from a protein sequence database hosted by NCBI. Automatic
homology modeling was attempted as a routine approach to the
3D structure of TSP50. NCBI-blast was performed, and we
observed a high degree of homology between the serine protease
family and TSP50.
Protein-model-building protocols, such as I-TASSER,
THREADER, HH-pred, and MODEL were used to produce
3D-structure of TSP50, with the hope of gaining a reliable result
[34,35,36]. Models with less probability were filtered out
according to the performance of fitting to some generally accepted
information about the characteristics of the active-site-based-
region of the serine protease family. At the end of the experiment,
the model built using the HH-pred web server to predict sequence-
alignments and MODEL to translate the alignments into 3D-
structure was found to be the best.
Stable Transfection
Transfections were performed using LipofectamineTM2000
(Invitrogen, CA, U.S.) according to the manufacturer’s instruc-
tions. 5610
5 CHO cells were seeded in each well of a 6-well plate
24 hours before transfection. The cells were transfected with 5 mg
of a wild-type TSP50 gene construct or the mutation construct.
The same cell line transfected with pcDNA3 empty plasmid was
used as a negative control. Transfected cells were incubated in the
presence of G418 for 2 weeks and stable transfected cell lines were
obtained.
RNA Extract and RT-PCR
Total RNA was isolated from cultured cells using Trizol reagent
(Invitrogen, Carlsbad, CA, U.S.) according to the manufacturer’s
instructions. RNA was quantified by measuring the absorbance
(A260 nm) and stored at –80uC until use. One microgram of total
RNA was reverse transcribed with oligo (dT) primers using
a reverse transcription system (TAKARA, Dalian, China). The
single-stranded cDNA was amplified by PCR using TSP50-specific
primer and b-actin primer pairs. PCR was performed for 30 cycles
(each cycle consisting of 94uC for 30 s, 54uC for 30 s, and 72uC for
30 s). The PCR products were analyzed by electrophoresis on
a 1% agarose gel. Primer sequences used were as follows: TSP50-
For CGGATCCATGCAGGGGAAGCC, Rev GCTCTA-
GAAGTCAGAGGGCAG; b-actin-For TCGTGCGTGACAT-
TAAGGAG, Rev ATGCCAGGGTACATGGTGGT.
Western Blot Analysis
Cells were harvested and rinsed twice with PBS. Cell extracts
were prepared with lysis buffer (1% Nonidet P-40, 50 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 1 mM NaF, 1 mM phenylmethyl-
sulfonyl fluoride, 4 mg/ml leupeptin, and 1 mg/ml aprotinin) for
30 min with occasional rocking followed by centrifugation at
12,000 rpm, for 10 min at 4uC. Identical amounts (100 mgo f
protein) of cell lysate were resolved by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS–PAGE). The
resolved proteins were electrophoretically transferred to poly-
vinylidenefluoride (PVDF) membrane, and blocked with 5% fat-
free dry milk in TBST (20 mM Tris-HCl (pH 7.6), 150 mM
NaCl, and 0.02% Tween20) for 1 h, at room temperature. The
membrane was immunoblotted with indicated antibodies in 1%
milk/TBST. To assure equivalent protein loading, the membranes
were simultaneously incubated with GAPDH monoclonal anti-
body (1:1000) overnight at 4uC. Membranes were washed three
times, incubated with HRP-conjugated secondary antibodies for
1 h at room temperature, and washed extensively before detection.
The membranes were subsequently developed using ECL reagent
(Beyotime, China) and exposed to film according to the
manufacturer’s protocol.
Cellular Localization
pEGFP-TSP50, pEGFP-TSP50 T310A, and the empty vector
pEGFP-N1 were transiently transfected into HEK293T cells. After
48 h, the cells were observed and photographed under a confocal
microscope.
Methyl Thiazolyl Tetrazolium (MTT) Assay
Cell proliferation was determined using the MTT assay. Cells
wereplated(1200cells/well)in200 mLofgrowthmediumin96-well
plates in three replicates, and a total of 8 plates were plated. Every
24 h, MTT (20 mM, Sigma Chemical Co.) was added to each well
for 4 h. The blue MTT formazan precipitate was dissolved in
100 mL of dimethylsulfoxide (DMSO). The absorbance at 570 nm
was measured on a micro-ELISA reader (Bio-Rad, CA, U.S.).
BrdU Incorporation Assay
The 5-bromo-20-deoxyuridine (BrdU) labeling and detection
ELISA kit was purchased from Roche Diagnostics (Mannheim,
Figure 7. T310A mutation decreases TSP50’s ability to interact with NF-kB:IkBa complex and to promote NF-kB signaling. (A)
Interaction between TSP50 and TSP50 T310A with NF-kB:IkBa complex. Equal amounts of protein from the cytoplasmic fraction of cells and
immunoprecipitates with anti-TSP50 antibodies were subjected to immunoblotting with antibodies as indicated. (B) and (C) Effects of TSP50 or TSP50
T310A on NF-kB activation. pcDNA3 cells, pcDNA3-TSP50 cells and pcDNA3-TSP50 T310A cells were treated with 100 ng/ml of PMA for 15 min, and
then (B) IkBa protein levels in these cells or (C) p65 protein levels in the nuclear fractions were detected by Western blotting, and quantitated using
ImageJ software. GAPDH was used as a loading control. Experiments were carried out in triplicate. (D) NF-kB luciferase reporter assay. HEK293T cells
were transiently transfected with pNF-kB-luc plasmid along with pcDNA3-TSP50, pcDNA3-TSP50 T310A, or pcDNA3 empty vector, respectively. Forty-
eight hours after transfection, cells were pretreated with 400 ng/ml of PMA for 15 min and luciferase activity was assayed. The results were expressed
as the fold activity in the luciferase activity of each sample versus that of the vector control. Three independent replicates of each experiment were
performed. (E) NF-kB CHIP assay. L02 cells transfected with pcDNA3 empty vector, pcDNA3-TSP50, and pcDNA3-TSP50 T310A were treated with
400 ng/ml of PMA for 15 min before harvesting. The anti-p65 antibodies were used for immunoprecipitation and cyclin D1 promoter fragments were
amplified and quantitated using ImageJ software. (F) Effects of TSP50 and TSP50 T310A on the PMA-induced expression of NF-kB target gene. L02
cells transfected with pcDNA3 empty vector, pcDNA3-TSP50 or pcDNA3-TSP50 T310A were treated with 100 ng/ml of PMA for 4 h, and then
cytoplasmic extracts were analyzed by Western blotting using antibodies against cyclinD1 and GAPDH. (G) and (H) Effects of TSP50 or TSP50 T310A
on the PMA-induced expression of NF-kB target genes. pcDNA3 cells, pcDNA3-TSP50 cells, and pcDNA3-TSP50 T310A cells were treated with PMA
(100 ng/ml) for 4 h, and then cytoplasmic extracts were analyzed by Western blotting using antibodies against (G) COX-2, (H) C-myc, and GAPDH.
doi:10.1371/journal.pone.0035030.g007
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tion of BrdU into newly synthesized molecules. pcDNA3,
pcDNA3-TSP50, and pcDNA3-TSP50 T310A cells were replated
at 1610
3 cells per well on 96-well plates. Twenty-four hours after
plating, BrdU labeling was initiated by adding labeling solution at
a final concentration of 10 mM to the culture medium. After 8 h
incubation, labeling was stopped. BrdU uptake was measured
according to the manufacturer’s instructions.
Colony Formation Assay
Cells were mixed in 0.35% Noble agar(in DMEM containing
10% fetal bovine serum) and plated at 5000 cells/well onto 6-well
plates containing a solidified bottom layer (0.6% Noble agar in the
same growth medium). After 15 days, colonies were either
unstained or stained with 5 mg/ml MTT (Sigma), and photo-
graphed, and three independent soft agar plating experiments
were performed for statistical analysis [37].
Figure 8. Reductions in the flexibility of the pocket-edge weaken TSP50’s ability to interact with NF-kB:IkBa complex. (A) The RMSF
values of every aC atom of TSP50 and TSP50 T310A models were calculated. (B) Distribution of sharp reductions of flexibility residues, represented as
sticks, is shown, and spheres represent Thr 310. This diagram was prepared using PyMOL.
doi:10.1371/journal.pone.0035030.g008
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pcDNA3 cells, pcDNA3-TSP50 cells, and pcDNA3-TSP50
T310A cells were seeded into fibronectin (Cat. no 1030-FN-01M
R&D Systems, Inc., 10 mg/ml)-coated six-well plates in 2 ml of
DMEM and cultured overnight. Pipette tips were used to scratches
in the cell monolayers. Then the monolayers were rinsed and
cultured for another 24 h. Pictures were taken at 0 and 24 h using
a digital camera system coupled to a microscope.
Cell Cycle Analysis
Cell cycle analysis based on the flow cytometry was performed
using Cell Cycle and Apoptosis Analysis Kit (Cat. no C1052
Beyotime Institute of Biotechnology, China) following the
manufacturer’s instructions.
Apoptosis Assay
Cells were treated with 5 mg/ml of DOX for 12 hours (for
TUNEL assay) or grew in complete medium for 96 hours (for
detection of Annexin V) and were stained with the TUNEL Assay
Kit (Cat. no 12 156 792 910 Roche Applied Sciences, Mannheim,
Germany) or Annexin V-FITC Apoptosis Detection Kit (Cat. no
KGA106 KeyGEN BioTECH, China) following the manufac-
turer’s instructions. Cells were then photographed under micro-
scope or analyzed by flow cytometry.
Tumorigenicity Assay
5610
6 cells were suspended in physiological saline and injected
subcutaneously into the backs of 7 BALB/C-scid mice. Tumor
volumes were determined using calipers. The greatest longitudinal
diameter (length) and the greatest transverse diameter (width) were
determined. Tumor volume was calculated using the modified
ellipsoidal formula [38].
Tumor volume=1/2(length6width
2) [39].
Immunohistochemical Assay
The tumor sections were fixed in 10% buffered formalin,
embedded in paraffin, and then deparaffinized and rehydrated
using standard procedures. For Ki67 staining, antigen retrieval
was performed in citrate buffer (pH 6.0, 30 min) and revealed
using a Ki67 rabbit polyclonal antibody. An immunohistochem-
istry kit (Maixin Bio, China) and DAB (diaminobenzidine) were
used as chromagen for Ki67. Negative (omission of the primary
antibody and substitution with preimmune serum) controls were
included in each slide run.
Co-immunoprecipitation
The Pierce Crosslink Immunoprecipitation Kit was purchased
from Thermo Scientific (U.S.) and the co-immunoprecipitation
experiments were performed according to the manufacturer’s
instructions.
Luciferase Reporter Assay
Firefly luciferase activity was measured 48 h after transfection.
Analysis of luciferase activity was performed as described
previously [11].
CHIP Assay
CHIP analysis of the cyclin D1 promoter using p65 antibodies
in L02 cells was performed 48 h after transfection as described
previously [40]. Cells were treated with 100 ng/ml of PMA for
15 min before the analysis. Sequences of primers for amplifying
cyclin D1 promoter were as follows: cyclinD1 sense
TCCCATTCTCTGCCGGGCTTTGATC; cyclinD1 antisense
GCTGGTGTTCCATGGCTGGGGC.
Statistical Analysis
Data are expressed as means 6 SD. Statistical analysis of the
data was performed using the Student’s t test. Values of P , 0.05
were considered statistically significant.
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